Duchenne Muscular Dystrophy (DMD), a severe hereditary disease, affecting 1 boy out of 3500, mainly results from the deletion of one or more exons leading to a reading frame shift of the DMD gene that abrogates dystrophin protein synthesis. We used the Cas9 of Staphylococcus aureus (SaCas9) to edit the human DMD gene.
INTRODUCTION
Duchenne muscular dystrophy is one of the most severe hereditary disease affecting 1 in 3500 new-born boys 1, 2 . This X-linked disorder is caused by a mutation in the DMD gene coding for the dystrophin protein leading to the absence of this protein in muscle fibers 3, 4 . These mutations, mostly deletions of one or several exons, are responsible of a shift in the normal reading frame of the DMD gene thus generating a premature stop codon leading to the loss of the dystrophin protein during the translation process. This protein is fundamental to maintain the integrity of the sarcolemma during contraction as it allows interaction with the surrounding extracellular matrix through binding with the membrane-anchored β-dystroglycan and with the cytoskeleton through interaction with actin and microtubules 5 . Notably, the dystrophin central rod domain is formed by 24 successive spectrin-like repeats (SLRs). Each of these SLRs is formed by three antiparallel α-helixes (A, B and C) forming a coiled-coiled structure, in which each heptad contains hydrophobic amino acids in positions "a" and "d". Interestingly, the nNOS interacts with the helixes A, B and C of the SLR 16 and with the helixes A of the SLR 17. It has been reported that in Becker muscular dystrophy (BMD) patients 6 , the severity of the disease could be related to the structure of their truncated dystrophin, thus we focused on creating a genomic deletion that not only restores the DMD gene reading frame but also allows the production of a dystrophin protein with SLRs correctly phased and structured.
Recent advances in the field of gene therapy offers great perspectives for the development of a curative treatment for DMD. Strategies of gene replacement that rely on the AAV-mediated delivery of micro-dystrophin still undergo development [7] [8] [9] and reached clinical trial phase such as the rAAVrh74.MHCK7.micro-dystrophin (Nationwide Children's Hospital Columbus, Ohio, United States) or the SGT-001 (University of Florida, Gainesville, Florida, United States) (https://clinicaltrials.gov/). However, few years ago, the discovery of the CRISPR/Cas9 system raised hope for the establishment of therapies for hereditary diseases, that counter the disease at its root, by editing the genome. This system was first identified as the immune system of some bacteria species such as Streptococcus pyogenes or Staphylococcus aureus, to protect them against bacteriophage infections 10 . This system has been adapted to target genomic DNA in mammals, thus offering possibilities to permanently edit their genome [11] [12] [13] . More precisely, a single guide RNA (sgRNA) can be made to target a specific protospacer sequence as long as it is positioned next to a protospacer adjacent motif (PAM), which is NGG for S. pyogenes and NNGRRT for S. aureus.
Once the Cas9/sgRNA complex binds to its protospacer, Cas9 protein is able to generate a double strand break precisely three nucleotides upstream of the SpCas9 or the SaCas9 PAM. Based on this precise editing capacity, we have previously shown that by using a combination of two sgRNAs, we can generate a genomic deletion that forms a hybrid exon 50-54, which restores the dystrophin protein expression in myotubes from a patient having a deletion of exons 51 to 53 14, 15 .
In DMD patients, reported mutations are mostly comprised in the "hot spot" including exons 45 to 55. To date, most of the research groups focus on the use of the CRISPR/Cas9 system to restore a normal reading-frame through the complete removal of one or several exons. which is not taking care to restore the normal phasing of spectrin-like repeat. Such approach could lead to the formation of a dystrophin protein with an abnormally structured central rod-domain, which can lead to a severe Becker Muscular Dystrophy instead of a milder BMD. Here we report an approach that covers up to 40% of all DMD mutations by creating a hybrid exon directly connecting exons 47 to 58 using the SaCas9. Please note that we did not form a hybrid exon 44-58 nor 45-58 because the dystrophin sequences of the SLR R17, coded by exons 44 to 46, are necessary for the essential interaction of dystrophin with nNOS 16 . Our approach will not only restore the dystrophin production but will also produce a dystrophin protein with a normal SLR structure. More precisely, by using a combination of 2 sgRNAs, we created a hybrid exon allowing to position hydrophobic amino acids in positions "a" and "d" of the newly formed SLR.
We think that by maintaining the adequate structure of the central rod domain, i.e., the SLRs, we can not only maintain the interaction of dystrophin with elements of the dystrophin-associated proteins and with nNOS but also insure the normal function of the dystrophin protein during contraction and relaxation of the muscle fibres. To precisely produce a normally phased SLR, we used our previously characterized CRISPR-induced deletion method (CinDel method) that aims to target into the exons that precede and follow the patient mutation to form a hybrid exon. We have, however, modified this approach to use the smaller SaCas9 from S. aureus whose gene could ultimately be delivered with a pair of sgRNAs by a single AAV 17 . Besides, we are not targeting the exons that immediately precede and follow the patient deletion but rather the exons 47 and 58 so that the formation of the hybrid exon 47-58 may be a therapeutic approach for any deletion, insertion or point mutations between these two exons. Our proposed edition would thus be a treatment for roughly 40% of DMD patients.
RESULTS

Identification and activity assays of individual sgRNAs in 293T cells
Our primary goal was to establish a strategy based on the creation of a hybrid exon allowing the correction of the DMD gene reading frame, in the case of DMD patients affected by the deletion of exon 50. Thus, all possible sgRNAs target sites in exons 46 to 58 were screened. We screened 51 sgRNA target sites for the SaCas9 nuclease. Since the SaCas9 nuclease induces a double strand break (DSB) at precisely 3 nucleotides upstream of the PAM (NNGRRT), we were able to select pairs of sgRNAs that can be combined to create a new hybrid exon that restores a normal reading frame. Thus, these hybrid exons might permit the production of an internally deleted dystrophin protein. In addition, we completed our analysis by selecting pairs of sgRNAs that were also able to produce an adequate SLR.
Consequently, we focused only on combinations where the hybrid junction maintained the configuration of a normal SLR where hydrophobic amino acids are localized in position "a" and "d" of the heptad motif (SLR are composed of 3 αhelixes, each containing 7 amino-acids (a to f) where hydrophobic amino acid are in the location "a" and "d"). In order to assess the adequate localization of those amino acids, we referred to the eDystrophin database, which provides information about the structural domains of the dystrophin protein (http://edystrophin.genouest.org/). As a result of our preliminary analysis, we focused our work on 18 sgRNAs (table 1 and Supplementary Figures S1A & B) , which can in principle generate 12 hybrid exons that do not only correct the reading frame of the DMD gene but also maintained the structure of the SLRs in the central rod domain (Supplementary Figure S1C ).
Next, we designed 18 sgRNAs, which were cloned into the PX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA plasmid (Addgene # 61591). These plasmids were, first individually, transfected in 293T cells to assess their activity.
Genomic DNA was extracted 48 hours post transfection. The targeted exon, either 46, 47, 49, 51, 52, 53 or 58 was amplified by PCR and submitted to a Surveyor assay for the detection of INDELs (Supplementary Figure S2A) . Among the 18 sgRNAs   tested, sgRNA 2-46, sgRNA 4-47, sgRNA 9-52, sgRNA 11-53, sgRNA 15-53 Figure S2B ).
Test of sgRNA pairs in 293T cells
293T cells were co-transfected with pairs of sgRNAs that might not only produce a large genomic deletion but also precisely connect exons, surrounding the deletion of the exon 50, to restore the reading frame and produce an adequate SLR. Thus, 12 pairs of sgRNAs (previously identified in a preliminary analysis of compatible sgRNAs) were tested. To detect the formation of the hybrid exons, PCRs were performed using the forward primer binding with the targeted exon upstream of the exon 50 and the reverse primer binding with the targeted exon downstream of the exon 50, previously used when sgRNAs were individually tested (Figure 1) . Given 
Analysis of hybrid exons
Before proceeding to further analyses, we needed to confirm that the hybrid exons that were formed were correct. Indeed, these hybrid exons should predominantly be able to restore a normal reading frame for the DMD gene. The PCR products resulting from the amplification of hybrid exons were purified and cloned into a pMiniT vector. For the analysis of the sequencing results of the hybrid exons, we counted the bacterial clones that contained the right nucleotide sequence and the bacterial clones that contained a hybrid exon where the nucleotide sequence was not exactly as expected (data not shown). To improve the characterization of these hybrid exons, we performed a modified TIDE analysis that compared a PCR product composed of 100% of the expected hybrid exon (amplified from a previously identified clone that contained a hybrid exon with the right nucleotide sequence), against a test sample amplified from the genomic DNA of treated cells (see Table 2 ). In at least 54% of the PCR products, the nucleotide sequences of the hybrid exons were exactly as candidates to produce dystrophin proteins with an adequate structure thus increasing the potential functionality of the newly produced internally-deleted dystrophin.
Formation of the hybrid exons 47-58 and restoration of dystrophin protein expression in DMD patient cells.
For the experiments with DMD patient cells, we only focused on the two pairs of sgRNAs that could be suitable for the highest number of DMD mutations, i.e., the Following the confirmation of the formation of the hybrid exon, myoblasts were grown until 100% confluence was reached and allowed to fuse into myotubes for at least 7 days in low serum medium. We observed that transduced myoblasts were still able to fuse into myotubes as eGFP expression was detected in myotubes ( Figure 4A) .
Next, the restoration of dystrophin expression was investigated with a western blot using an anti-dystrophin antibody (NCL-Dys2, Novocastra) in treated and non-treated myotubes ( Figure 4B) . 
Off-target analysis
For the analysis of the possible off-target mutations, we focused our study on the best two pairs of sgRNAs (i.e., sgRNAs 3-47/16-58 and sgRNAs 5-47/18-58). The potential off-target sites were identified with the in silico tools provided on the website http://www.benchling.com which is calculated using an algorithm developed by Hsu et al. 19 . For each sgRNA, we considered the top 10 high scores of off-targets with the most permissive PAM, meaning NNGRR in addition to NNGRRT. We choose to focus only on off-targets related to annotated genes. For the sgRNA 3-47, the highest off-target score identified was 2,5. However, none of the 10 off-targets with the highest scores were related to an annotated gene. The sgRNA 5-47, had potential off-targets with scores below 0,8 and no annotated genes. The sgRNA 16-58 showed off-target scores ranging from 7,4 to 0,8. Its highest off-target was the IL-17A gene localized in the chromosome 6 (position +52190188). Interestingly, the off-target site in the IL-17A gene is localized in its intron 3 after the stop codon. Thus, even if offtarget mutations would occur in this localization, they would have no impact on the IL- contained 83 % of the right nucleotide sequence (Figure 5D ). Following protein extraction, the western blot analysis confirmed that the de novo expressed dystrophin in the heart, corresponded with the size of the internally truncated dystrophin that we aimed to create (Figure 5C ). Together, these results demonstrate that our approach is suitable for in vivo applications.
DISCUSSION
Over the past five years, several CRISPR-based approaches have been investigated for the development of therapies for DMD. Single-cut genome editing relies on the alteration of splice-acceptor sequences to splice out the targeted exon to restore the normal reading frame in the mature mRNA leading to the production of dystrophin protein [21] [22] [23] [24] [25] [26] . Other groups develop strategies that rely on the complete removal of one or several exons to restore the DMD gene reading frame using a pair of sgRNAs inducing DSB in introns [26] [27] [28] . The edition of the dystrophin gene by Homology Directed Repair (HDR) has also been investigated, by the treatment of muscle stem cells followed by their engraftment or by the direct delivery of nanoparticles formed by a complex between a Cas9/sgRNA and a donor DNA 26, 29, 30 . This approach restored the dystrophin gene and full-length dystrophin protein, but it remains limited to in situ treatment only.
Current strategies, that rely on exon skipping or deletion of one or several complete exons, do not consider the structure of the dystrophin protein and the phasing of the SLR that results from splicing out or deletions of these exons. As reported by Le
Rumeur's group 6 the abnormal structure of the SLRs that form the central rod domain of the dystrophin protein could be responsible for the severity and disease progression of Becker Muscular Dystrophy (BMD). Indeed, dystrophin from some BMD patients harbouring large in-frame deletions can still be functional and lead to a milder phenotype 31 . Thus, features learned from BMD patients is of major interest for research groups that develop mini and micro-dystrophin whose works mainly focus on the designing a truncated dystrophin protein, which nevertheless contained adequate functional structural domain 32 . Interestingly, it has been shown that microdystrophins having SLRs correctly phased improved its function in comparison to abnormal SLRs.
Several researchers have worked for many years to produce a mini or a microdystrophin gene that not only produces a protein but that also codes for a protein with an optimal structure to insure a good function [33] [34] [35] [36] [37] [38] [39] [40] . Since an adequate structure is a very important for a mini and a micro-dystrophin gene, the structure of the dystrophin protein produced by a CRISPR/Cas9 modification should also be carefully taken in consideration. In a previous work, we used the SpCas9 to induce precise deletion to form the hybrid exon 50-54, through induction of double strand breaks at precise genomic sites. The main advantage of the SaCas9 over the SpCas9 is that its smaller size could in principle permit to insert its gene as well as 2 sgRNAs in only one AAV. This great advantage, for an eventual clinical application, would not only reduce the cost of the treatment but moreover every cell infected by the unique AAV vector would have all the components required to produce the hybrid exon. However, the development of such product requires further development to obtain this all in one vector, which requires a promoter smaller than the CMV that allow expression of SaCas9 in skeletal muscle and cardia cells only, along with sgRNA promoter that exhibits enough activity.
Consequently, our research group considered that it could be highly relevant to focus on the development of a CRISPR-based therapy that not only restores the DMD gene reading frame but also aims to form a normal SLR that mimics the dystrophin protein present in BMD patients with no severe symptoms. The aim of our project was to provide proof of principle for a therapeutic approach using the CRISPR/SaCas9 technology for DMD patients harbouring different mutations in their DMD gene. In a previous publication, our team demonstrated that through the use of the Cas9 of However, this strategy was only suitable for DMD patients affected by a mutation of their DMD gene between exons 50 and 54. Based on a similar approach, we aimed in the present project to form a hybrid exon that could provide a therapy for a higher percentage of DMD patients. In addition, we choose to design our approach using SaCas9, which is smaller than SpCas9 and could thus be delivered by a single AAV coding for the SaCas9 gene and a pair of sgRNAs.
Previous works had already demonstrated the ability of the SaCas9 nuclease and a pair of sgRNAs to edit the mdx gene in the mdx -/-mouse, a dystrophic model, by removing completely the mutated exon 23 that consequently restored the expression of dystrophin 26, 27, 41 . Here, we report for the first time the use of the SaCas9 to edit gene, which could be problematic in DMD patients. Even if this off-target site is located within a non-coding segment of the IL-17A gene, strategies to limit possible adverse effects would have to be considered. A possible strategy would be to use a skeletal muscle and cardiac tissue specific promoter, such as the CK8e promoter developed by Hauschka's laboratory 21, 26, 44 , which restricts the expression of the nuclease to tissues where editing is required to improve the DMD patient phenotype.
In addition, the development of tools, which prevent the sustained expression of CRISPR nucleases, are required to restrain the nuclease expression to the minimal time period required for a sufficient editing of the target gene 45, 46 , while limiting the occurrence of off-target mutations. Here we empirically assessed the potential offtargets of our sgRNAs based on an in silico prediction tool. This tool, and other similar ones, identify off-targets based on the position of one or several mismatches in the sgRNA 19, 47 but several articles have reported that the sites of predicted offtarget mutations are not always reliable 48 . Ultimately, a pre-clinical study should characterize more extensively the overall off-target mutations of sgRNA 3-47 and 16-58 using un-biased high throughput next generation sequencing [49] [50] [51] .
Our follow-up study will aim to improve the overall DMD gene editing in vivo, in young del52hDMD/mdx mouse, to restore dystrophin protein expression in the diaphragm and skeletal muscle in addition to the heart. We will also assess whether the formation of hybrid exons, such as the hybrid exon 47-58, which maintains the SLR structure, results in a more substantial functional improvement in comparison to the editing of the DMD gene by the removing of one or several full exons, without maintaining the correct phasing of the SLR.
MATERIALS & METHODS
Identifications of DNA targets and sgRNA cloning
For the identification of the sgRNA targets, we used the website www.benchling.com.
Based on the DMD gene sequence (ENSG00000198947), we identified all the PAMs "NNGRRT" for the Cas9 for Staphylococcus aureus from in the exons 46 to 58.
Oligonucleotides corresponding to the sgRNAs of interest were ordered from Integrated DNA Technology (Coralville, IA). Suspension was then centrifuged at 13200 rpm for 5 min. The supernatant was collected in a new microfuge tube. One volume of phenol-chloroform was added and following centrifugation, the aqueous phase was recovered in a new microfuge tube.
Expression vector and cloning of sgRNAs
Then DNA was precipitated using 1/10 volume of NaCl 5 M and two volumes of 100% ethanol followed by 5 min centrifugation at 13200rpm. The pellet was washed with 70% ethanol, centrifuged and the DNA was suspended in double-distilled water.
The genomic DNA concentration was assayed with a Nanodrop TM spectrophotometer (Thermo Scientific, Logan, UT).
Assessment of the formation by sgRNAs of INDELs on on-target and off-target.
Genomic region targeted by a sgRNA (either on-target or off-target sequences) were amplified by PCR before further analysis. First, cleavage efficiency was assessed by Surveyor assay according to manufacturer's instruction. PCR products were then sequenced and the resulting .ab files were used for their characterization using the TIDE tool provided on https://tide.deskgen.com 52 . Amplifications of genomic DNA from untreated cells were used as control sample. For deep-sequencing analysis, new sets of primers were designed to permit the amplification of PCR products no longer than 350 bp.
Assessment of the formation of hybrid exons
For the characterization of the nucleotide sequence of the hybrid exons, PCR product corresponding to the amplification of these hybrid exons were cloned into pMiniT plasmid vector of a PCR cloning kit following manufacturer's instruction (NEB, Ipswich, USA). After transformation into bacteria and clone growth in a liquid medium, plasmidic DNA was extracted and purified for sequencing.
The TIDE analysis tool was used to characterize of the rate of formation of perfect hybrid exons. As a control sample, hybrid exons that contained the exact nucleotide sequence, previously inserted in a pMiniT vector and sequenced, were amplified by PCR and were used as control sample for the analysis. As a test sample, pools of PCR products amplified from treated cells were used.
Lentivirus production
A lentiviral vector that allows for the expression of the SaCas9 along with 2 sgRNAs was constructed starting from the plasmid FUGW (Addgene # 14883). First, the Transduction efficiency was assessed 48 h after medium replacement by observing eGFP fluorescence.
Western blot analysis
After the fusion of myoblasts into myotubes, proteins were extracted using a protein lysis buffer (75 mM Tris-HCl pH 8.0, 1 mM DTT, 1 mM PMSF, 1% SDS). The protein concentrations were determined using an amido-black assay 53 
Production of AAV9 viral vectors
All viral vectors were produced by the Molecular Tools Platform of the CRIUSMQ (Québec, Canada). The AAV9 vector that encodes the SaCas9 gene under the control of the CMV promoter was produced from the plasmid PX601 (Addgene Inc., Cambridge, MA). Two AAV9 vectors that permitted the expression of a pair of sgRNAs were produced from the plasmid pBSU6 (pBSU6_FE_Scaffold_RSV_GFP, Dirk Grimm Lab, Heidelberg University, Germany).
In vivo experiments.
Three AAV9 vectors were designed to determine the in vivo feasibility of the 
Targeted deep-sequencing and bioinformatics analysis
For deep-sequencing analysis, primers were redesigned to allow the amplification of Table 2 , which could in principle restore an open readingframe for the DMD gene. The formation of the hybrid exon was confirmed by PCR amplification, (i.e., there was no PCR product when the hybrid exon is not formed).
As a negative control (Ct) we used non-transfected 293T cells. Myoblasts from a healthy subject (WT) and from 4 DMD patients with different exon deletion were infected with the lentivirus coding for SaCas9, a pair of sgRNAs and eGPF, and allowed to fuse into myotubes for at least 7 days in low serum medium.
EGFP expression allowed to observe that myoblasts infected with the lentivirus were able to fuse into myotubes. (B) The myotube proteins were then extracted and submitted to a western blot analysis for the detection of the dystrophin protein using an anti-dystrophin monoclonal antibody (NCL-Dys2, Novocastra). 
